Eiger BioPharmaceuticals, Inc. Announces Sriram Ryali to Resign as Chief Financial Officer, Effective January 20, 2023

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its portfolio also includes avexitide, a well-characterized GLP-1 antagonist, as a targeted treatment for two metabolic diseases with high unmet medical needs. The avexitide is a GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, Peginterferon Lambda (lambda) for COVID-19, Avexitide for Congenital Hyperinsulinism (HI) and Avexitide for Post-Bariatric Hypoglycemia (PBH). LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection.